Telix Pharmaceuticals Limited has agreed to acquire RLS, a Joint Commission-accredited radiopharmacy network distributing PET, SPECT and therapeutic radiopharmaceuticals, from its parent company, RLS Group Ltd.   This move significantly expands Telix’s North American manufacturing footprint and establishes the basis of a next-generation radiometal production network to benefit Telix and select strategic commercial partners.   This news comes months after Telix entered into an agreement to ac...